Editorial
doi: 10.1002/cncr.30740.
Epub 2017 May 2.
Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?
Affiliations
- PMID: 28464215
- PMCID: PMC5738913
- DOI: 10.1002/cncr.30740
Item in Clipboard
Editorial
Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?
Cancer.
.
No abstract available
Comment on
-
Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.Cancer. 2017 Sep 1;123(17):3326-3334. doi: 10.1002/cncr.30739. Epub 2017 May 2. Cancer. 2017. PMID: 28464214
Similar articles
-
R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphoma.Asia Pac J Clin Oncol. 2020 Dec;16(6):385-391. doi: 10.1111/ajco.13396. Epub 2020 Aug 10. Asia Pac J Clin Oncol. 2020. PMID: 32779387
-
Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.Histopathology. 2013 Dec;63(6):788-801. doi: 10.1111/his.12223. Epub 2013 Oct 1. Histopathology. 2013. PMID: 24117687
-
Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.Med Oncol. 2022 Jan 29;39(4):44. doi: 10.1007/s12032-021-01642-3. Med Oncol. 2022. PMID: 35092504
-
Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era.Leuk Lymphoma. 2015 Jul;56(7):1959-68. doi: 10.3109/10428194.2014.979412. Epub 2015 Jan 21. Leuk Lymphoma. 2015. PMID: 25363401 Review.
-
Treatment of diffuse large B-cell lymphoma: a risk-based approach.Clin Lymphoma Myeloma. 2006 Oct;7 Suppl 1:S14-9. doi: 10.3816/clm.2006.s.003. Clin Lymphoma Myeloma. 2006. PMID: 17101068 Review.
Cited by
-
Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.BMC Med. 2022 Oct 25;20(1):369. doi: 10.1186/s12916-022-02562-3. BMC Med. 2022. PMID: 36280874 Free PMC article.
-
A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.Cancer. 2019 Jun 1;125(11):1837-1847. doi: 10.1002/cncr.31981. Epub 2019 Feb 1. Cancer. 2019. PMID: 30707765 Free PMC article.
-
Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma.Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):234-243.e10. doi: 10.1016/j.clml.2019.12.003. Epub 2019 Dec 24. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32063526 Free PMC article.
-
Predictive value of baseline 18F-FDG PET/CT and interim treatment response for the prognosis of patients with diffuse large B-cell lymphoma receiving R-CHOP chemotherapy.Oncol Lett. 2021 Feb;21(2):132. doi: 10.3892/ol.2020.12393. Epub 2020 Dec 18. Oncol Lett. 2021. PMID: 33552253 Free PMC article.
-
To Determine the Prognostic Significance of 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan-Derived Parameters (Total Lesion Glycolysis and Metabolic Tumor Volume) in Patients of Diffuse Large B-Cell Lymphoma with Only Nodal Involvement.Indian J Nucl Med. 2020 Apr-Jun;35(2):100-104. doi: 10.4103/ijnm.IJNM_6_20. Epub 2020 Mar 12. Indian J Nucl Med. 2020. PMID: 32351262 Free PMC article.
References
-
- Howlader N, et al. Cancer-Specific Mortality, Cure Fraction, and Non-Cancer Causes of Death among Diffuse Large B-cell Lymphoma Patients in the Immunochemotherapy Era. (2017 INSERT REFERENCE HERE) - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
